Market Overview

A Peek Into The Market Before The Trading Starts

Related VRA
Weakness Seen in Vera Bradley (VRA) Estimates: Should You Stay Away? - Tale of the Tape
What Makes Vera Bradley (VRA) a Strong Sell? - Tale of the Tape
Related PIR
Specialty Retail Peers Shrug Off Warning From The Container Store (BBBY, PIR, WSM)
Bed Bath & Beyond Q1 Earnings Preview: Will Earnings Go Beyond Expectations?

Pre-open movers US stock futures are mostly flat this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average dropped 3 points to 13,227.00 and S&P 500 index futures fell 1.70 points to 1,425.50. Nasdaq 100 futures declined 1.50 points to 2,668.75.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.29%, London's FTSE 100 Index dropped 0.25%, French CAC 40 Index declined 0.05% and German DAX 30 index fell 0.32%.

Asian markets ended mostly lower, with Japan's Nikkei Stock Average rising 1.68%, China's Shanghai Composite dropping 1.02% and Australia's S&P/ASX 200 rising 0.02%. Hong Kong's Hang Seng Index fell 0.26% and India's Sensex dropped 0.65%.

Broker Recommendation Analysts at Jefferies upgraded Vera Bradley (NASDAQ: VRA) from “hold” to “buy.” The target price for Vera Bradley has been raised from $22 to $35.

Vera Bradley shares gained 1.41% to $24.48 in pre-market trading.

Breaking news

  • Pier 1 Imports (NYSE: PIR) reported a 3% rise in its fiscal third-quarter earnings and lifted its full-year earnings forecast. To read the full news, click here.
  • International Game Technology (NYSE: IGT) today announced it has agreed to a deal to provide mobile games to Paddy Power in a significant extension to the companies' existing partnership. To read the full news, click here.
  • Oncolytics Biotech (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018). To read the full news, click here.
  • ReachLocal (NASDAQ: RLOC) today announced that its Board of Directors has amended its previously announced share repurchase program to increase the total authorized repurchase amount by $6 million, to a total authorization of $26 million. To read the full news, click here.

Posted-In: Jefferies US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Most Popular

Related Articles (ONCY + IGT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters